EquitySector - HealthcareVery High Risk
Direct
NAV (17-Apr-25)
Returns (Since Inception)
Fund Size
₹83 Cr
Expense Ratio
1.22%
ISIN
INF397L01LK4
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
28 Feb 2019
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+19.78%
+17.55% (Cat Avg.)
3 Years
+16.88%
+18.10% (Cat Avg.)
5 Years
+19.64%
+22.46% (Cat Avg.)
Since Inception
+20.06%
— (Cat Avg.)
Equity | ₹81.06 Cr | 98.03% |
Others | ₹1.63 Cr | 1.97% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹8.29 Cr | 10.03% |
Piramal Pharma Ltd | Equity | ₹4.88 Cr | 5.90% |
Torrent Pharmaceuticals Ltd | Equity | ₹4.37 Cr | 5.29% |
Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹4.21 Cr | 5.09% |
Glenmark Pharmaceuticals Ltd | Equity | ₹3.79 Cr | 4.59% |
Cipla Ltd | Equity | ₹3.52 Cr | 4.26% |
Divi's Laboratories Ltd | Equity | ₹3.25 Cr | 3.93% |
Alkem Laboratories Ltd | Equity | ₹3.13 Cr | 3.78% |
Abbott India Ltd | Equity | ₹3.07 Cr | 3.71% |
Syngene International Ltd | Equity | ₹2.95 Cr | 3.57% |
Apollo Hospitals Enterprise Ltd | Equity | ₹2.91 Cr | 3.52% |
Global Health Ltd | Equity | ₹2.9 Cr | 3.51% |
Navin Fluorine International Ltd | Equity | ₹2.88 Cr | 3.49% |
Ipca Laboratories Ltd | Equity | ₹2.84 Cr | 3.43% |
Dr Agarwal’s Health Care Ltd | Equity | ₹2.77 Cr | 3.36% |
Neuland Laboratories Limited | Equity | ₹2.72 Cr | 3.29% |
OneSource Specialty Pharma Ltd | Equity | ₹2.58 Cr | 3.13% |
Mankind Pharma Ltd | Equity | ₹2.58 Cr | 3.12% |
Aurobindo Pharma Ltd | Equity | ₹2.5 Cr | 3.03% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹2.47 Cr | 2.99% |
Treps | Cash - Repurchase Agreement | ₹2.43 Cr | 2.94% |
Vinati Organics Ltd | Equity | ₹2.35 Cr | 2.84% |
Zydus Lifesciences Ltd | Equity | ₹2.31 Cr | 2.79% |
Concord Biotech Ltd | Equity | ₹1.88 Cr | 2.27% |
Metropolis Healthcare Ltd | Equity | ₹1.84 Cr | 2.23% |
Laurus Labs Ltd | Equity | ₹1.62 Cr | 1.96% |
Suven Pharmaceuticals Ltd | Equity | ₹1.6 Cr | 1.94% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹0.84 Cr | 1.02% |
Net Receivables / (Payables) | Cash - Collateral | ₹-0.8 Cr | 0.97% |
Large Cap Stocks
26.29%
Mid Cap Stocks
28.75%
Small Cap Stocks
33.22%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹73.11 Cr | 88.41% |
Basic Materials | ₹5.23 Cr | 6.33% |
Standard Deviation
This fund
16.51%
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
0.69
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Since July 2023
ISIN INF397L01LK4 | Expense Ratio 1.22% | Exit Load 1.00% | Fund Size ₹83 Cr | Age 6 years 1 month | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Total AUM
₹1,942 Cr
Address
4th Floor, Industrial Assurance Building, Mumbai, 400 020
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
LIC MF Gold ETF FOF Direct Growth High Risk | 0.2% | 1.0% | ₹103.66 Cr | 28.8% |
LIC MF Equity Savings Fund Direct Growth Moderately High risk | 1.3% | 1.0% | ₹19.12 Cr | 9.4% |
LIC MF Nifty Next 50 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹91.22 Cr | 3.8% |
LIC MF Focused 30 Equity Direct Growth Very High Risk | 1.6% | 1.0% | ₹127.19 Cr | 8.4% |
LIC MF Long Term Value Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹148.90 Cr | 6.4% |
LIC MF Healthcare Fund Direct Growth Very High Risk | 1.2% | 1.0% | ₹82.69 Cr | 19.8% |
LIC MF Small Cap Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹493.73 Cr | 11.1% |
LIC MF Midcap Fund Direct Growth Very High Risk | 1.3% | 1.0% | ₹301.59 Cr | 11.3% |
LIC MF Dividend Yield Fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹490.38 Cr | 13.6% |
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Direct
NAV (17-Apr-25)
Returns (Since Inception)
Fund Size
₹83 Cr
Expense Ratio
1.22%
ISIN
INF397L01LK4
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
28 Feb 2019
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+19.78%
+17.55% (Cat Avg.)
3 Years
+16.88%
+18.10% (Cat Avg.)
5 Years
+19.64%
+22.46% (Cat Avg.)
Since Inception
+20.06%
— (Cat Avg.)
Equity | ₹81.06 Cr | 98.03% |
Others | ₹1.63 Cr | 1.97% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹8.29 Cr | 10.03% |
Piramal Pharma Ltd | Equity | ₹4.88 Cr | 5.90% |
Torrent Pharmaceuticals Ltd | Equity | ₹4.37 Cr | 5.29% |
Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹4.21 Cr | 5.09% |
Glenmark Pharmaceuticals Ltd | Equity | ₹3.79 Cr | 4.59% |
Cipla Ltd | Equity | ₹3.52 Cr | 4.26% |
Divi's Laboratories Ltd | Equity | ₹3.25 Cr | 3.93% |
Alkem Laboratories Ltd | Equity | ₹3.13 Cr | 3.78% |
Abbott India Ltd | Equity | ₹3.07 Cr | 3.71% |
Syngene International Ltd | Equity | ₹2.95 Cr | 3.57% |
Apollo Hospitals Enterprise Ltd | Equity | ₹2.91 Cr | 3.52% |
Global Health Ltd | Equity | ₹2.9 Cr | 3.51% |
Navin Fluorine International Ltd | Equity | ₹2.88 Cr | 3.49% |
Ipca Laboratories Ltd | Equity | ₹2.84 Cr | 3.43% |
Dr Agarwal’s Health Care Ltd | Equity | ₹2.77 Cr | 3.36% |
Neuland Laboratories Limited | Equity | ₹2.72 Cr | 3.29% |
OneSource Specialty Pharma Ltd | Equity | ₹2.58 Cr | 3.13% |
Mankind Pharma Ltd | Equity | ₹2.58 Cr | 3.12% |
Aurobindo Pharma Ltd | Equity | ₹2.5 Cr | 3.03% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹2.47 Cr | 2.99% |
Treps | Cash - Repurchase Agreement | ₹2.43 Cr | 2.94% |
Vinati Organics Ltd | Equity | ₹2.35 Cr | 2.84% |
Zydus Lifesciences Ltd | Equity | ₹2.31 Cr | 2.79% |
Concord Biotech Ltd | Equity | ₹1.88 Cr | 2.27% |
Metropolis Healthcare Ltd | Equity | ₹1.84 Cr | 2.23% |
Laurus Labs Ltd | Equity | ₹1.62 Cr | 1.96% |
Suven Pharmaceuticals Ltd | Equity | ₹1.6 Cr | 1.94% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹0.84 Cr | 1.02% |
Net Receivables / (Payables) | Cash - Collateral | ₹-0.8 Cr | 0.97% |
Large Cap Stocks
26.29%
Mid Cap Stocks
28.75%
Small Cap Stocks
33.22%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹73.11 Cr | 88.41% |
Basic Materials | ₹5.23 Cr | 6.33% |
Standard Deviation
This fund
16.51%
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
0.69
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Since July 2023
ISIN INF397L01LK4 | Expense Ratio 1.22% | Exit Load 1.00% | Fund Size ₹83 Cr | Age 6 years 1 month | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Total AUM
₹1,942 Cr
Address
4th Floor, Industrial Assurance Building, Mumbai, 400 020
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
LIC MF Gold ETF FOF Direct Growth High Risk | 0.2% | 1.0% | ₹103.66 Cr | 28.8% |
LIC MF Equity Savings Fund Direct Growth Moderately High risk | 1.3% | 1.0% | ₹19.12 Cr | 9.4% |
LIC MF Nifty Next 50 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹91.22 Cr | 3.8% |
LIC MF Focused 30 Equity Direct Growth Very High Risk | 1.6% | 1.0% | ₹127.19 Cr | 8.4% |
LIC MF Long Term Value Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹148.90 Cr | 6.4% |
LIC MF Healthcare Fund Direct Growth Very High Risk | 1.2% | 1.0% | ₹82.69 Cr | 19.8% |
LIC MF Small Cap Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹493.73 Cr | 11.1% |
LIC MF Midcap Fund Direct Growth Very High Risk | 1.3% | 1.0% | ₹301.59 Cr | 11.3% |
LIC MF Dividend Yield Fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹490.38 Cr | 13.6% |
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments